Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301Antonius A. Miller, Mark J. Ratain, Lionel D. Lewis et al.|Journal of Clinical Oncology|2009Cited by 207
Phase I and Pharmacokinetic Study of Erlotinib for Solid Tumors in Patients With Hepatic or Renal Dysfunction: CALGB 60101Antonius A. Miller, Mark J. Ratain, Daryl J. Murry et al.|Journal of Clinical Oncology|2007Cited by 68
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropeniaLionel D. Lewis, Mark J. Ratain, Antonius A. Miller et al.|Pharmacogenetics and Genomics|2012Cited by 27
Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome:<scp>CALGB</scp>10105 (<scp>A</scp>lliance)Xiaofeng Wang, Daryl J. Murry, Kouros Owzar et al.|British Journal of Clinical Pharmacology|2014Cited by 10
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance)Howard L. McLeod, Antonius A. Miller, Kouros Owzar et al.|eScholarship (California Digital Library)|2020Cited by 3